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Anthrax lethal toxin (LT)-induced cell death
via mitogen-activated protein kinase kinase
(MAPKK) cleavage remains questionable.
Here, a chemical genetics approach was used
to investigate what pathways mediate LT-
induced cell death. Several small molecules
were found to protect macrophages from an-
thrax LT cytotoxicity andMAPKK from cleavage
by lethal factor (LF), without inhibiting LF
enzymatic activity or cellular proteasome activ-
ity. Interestingly, the compounds activated
MAPK-signaling molecules, induced proinflam-
matory cytokine production, and inhibited
LT-induced macrophage apoptosis in a con-
centration-dependent manner. We propose
that induction of antiapoptotic responses by
MAPK-dependent or -independent pathways
and activation of host innate responses may
protect macrophages from anthrax LT-induced
cell death. Altering host responses through
a chemical genetics approach can help identify
critical cellular pathways involved in the patho-
genesis of anthrax and can be exploited to
further explore host-pathogen interactions.
INTRODUCTION
Host-pathogen interactions are regulated both by viru-
lence factors and by host components that either protect
the host or promote pathogenesis. Historically, significant
efforts have focused on identifying microbial targets for
the development of both therapeutic and preventive mea-
sures, while the host factors involved in microbial patho-
genesis have not been fully explored. Identifying host pro-
teins that are involved in the pathogenesis of a microbial
disease and developing host-oriented therapeutics willChemistry & Biology 14, 24help circumvent the problems of acquired or engineered
resistance to existing antimicrobials.
Secreted by Bacillus anthracis, anthrax lethal toxin (LT),
a pore-forming heterocomplex of protective antigen (PA)
and lethal factor (LF), cleaves several members of the mi-
togen-activated protein kinase kinase (MAPKK/MEK) fam-
ily [1–3]. Recent studies suggest that LT severely impairs
the host immune response by disrupting the MAP ki-
nase-signaling network in macrophages [1–4] and in den-
dritic cells [5, 6], thereby allowing the growth of bacteria
and establishment of infection. However, cytotoxicity
studies revealed that cultured macrophages from inbred
mouse strains vary in their sensitivity to LT-induced cell
death [3, 7]. Certain mouse strains whose macrophages
are resistant to LT-induced cytotoxicity exhibit MAPKK
cleavage [3]. In a recent study, we showed a relationship
between LT-induced MAPKK cleavage and impaired
bactericidal activity of nonhuman primate alveolar macro-
phages in the absence of cell death [8]. Thus, these stud-
ies suggest that there is no direct relationship between
MAPKK cleavage and susceptibility to LT-induced cyto-
toxicity and that other cellular proteins besides MAPKK
may be involved in anthrax pathogenesis.
An emerging technology, chemical genetics utilizes
small organic molecules as probes in high-throughput
cell-based screening assays to identify critical signaling
pathways that regulate biological function [9, 10]. To bet-
ter understand the mechanism of anthrax LT-induced cell
death, we used a diverse library of small molecules to per-
turb macrophage function during anthrax LT treatment.
Cell viability assays identified several compounds that
protected macrophages from LT-induced cell death.
These compounds did not inhibit in vitro LF enzymatic
activity or cellular proteasome activity. However, the
compounds did protect MAPKK from cleavage by LF in
macrophages, thus suggesting that the activation or inhi-
bition of cellular factor(s) was responsible for the observed
macrophage viability following LT treatment. The com-
pounds activated ERK1/2, p38, and SAPK/JNK MAPK-
signaling molecules and inhibited LT-induced apoptosis
of macrophages. Possible induction of antiapoptotic5–255, March 2007 ª2007 Elsevier Ltd All rights reserved 245
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Chemical Genetics to Understand Anthrax PathogenesisFigure 1. Bioactive Small Molecules
Protect Macrophages from the Lethal
Action of Anthrax Toxin and Do Not
Inhibit Proteasome Activity
(A) J774A.1macrophageswere pretreated with
medium containing DMSO (control) or with the
small molecules for 30 min and then further
incubated with the anthrax LT. After 4 hr, cell
viability was measured using a MTT assay.
The data represent the averages ± SD for three
independent experiments.
(B) Live imaging of J774A.1 macrophages
treated with anthrax LT alone (top panel) or
with the anthrax toxin and compound NSC
95397 (bottom panel) in the presence of the
membrane-impermeable SYTOX green dye.
The 4 hr incubation time is shown in the figure.
(C) Compounds do not inhibit proteasome ac-
tivity. Cell lysates prepared from untreated
J774A.1 cells were incubated with 100 mM of
the different fluorogenic peptide substrates
(SLLVY-AMC, Z-LLE-AMC, and Z-VKM-AMC)
in the presence of either medium containing
DMSO (control), compound NSC 270012
(20 mM), NSC 95397 (20 mM), or MG132 (10 mM).
Increased fluorescence was measured at an
excitation wavelength of 380 nm and an emis-
sion wavelength of 460 nm using a fluores-
cence plate reader. Data shown are from the
30 min incubation time point. The data repre-
sent the averages ± SD for three independent
experiments.genes through MAPK-dependent or -independent path-
ways may be responsible for the observed phenotype.
RESULTS
Small Molecules Protect Macrophages from Anthrax
Lethal Toxin-Induced Cytotoxicity but Do Not Inhibit
LF or Proteasome Activity
To identify compounds that inhibit anthrax lethal toxin cy-
totoxicity, we screened a chemically diverse set of small
molecules from the National Cancer Institute (NCI) Open
Chemical Repository (1000 compounds) in a toxin-
induced cell death assay. J774A.1 macrophages in multi-
well plates were preincubated with either medium con-
taining DMSO (control) or compounds, and then anthrax
toxin was added. Cell viability was determined using
a MTT dye assay. Five compounds, NSC 148596, NSC
135880, NSC 95397, NSC 270011, and NSC 270012, in-
hibited anthrax LT cytotoxicity with ED50 values ranging
from 5 to 25 mM (Figure 1A). At concentrations above 25
mM, the compounds themselves were toxic to the cells,
but below 25 mM their efficacy to enhance survival in-
creased in a dose-dependent manner. We confirmed the
protective effect of the most potent compound, NSC
95397, by visualizing with time-lapse imaging the uptake
of the membrane-impermeable SYTOX green dye by
dead cells (for complete movies, see Movies S1 and S2).
When treated with both NSC 95397 and toxin, relatively
few macrophages took up the dye (Figure 1B, bottom
panel) compared to those treated with toxin alone246 Chemistry & Biology 14, 245–255, March 2007 ª2007 Elsevi(Figure 1B, top panel), thus showing that the compound
could indeed protect J774A.1 macrophages from the le-
thal action of anthrax toxin.
To determine if the identified compounds protected
J774A.1 cells by inhibiting LF enzymatic activity, we
tested all five compounds in vitro using an HPLC-based
LF assay [11]. None of the compounds inhibited the ability
of LF to cleave peptide substrate (data not shown), sug-
gesting that the compounds protected the cells by acting
on a cellular component within the macrophages.
The proteasome, a multicatalytic protease, causes ex-
tralysosomal degradation of cellular proteins and plays
a role in apoptosis [12]. Functional proteasome activity is
reported to be indispensable for anthrax LT to kill macro-
phage-like cell lines such as RAW264.7 [13]. To determine
if the identified compounds inhibited proteasome activity
in macrophages, protein lysates from macrophages
were incubated with three different fluorogenic protea-
some substrates (LLE, LLVY, and VKM) in the presence
of either NSC 95397, NSC 270012, or a known protea-
some inhibitor, MG132. As shown in Figure 1C, neither
NSC 95397 nor NSC 270012 inhibited proteasome activity
compared to MG132, suggesting that they protected
anthrax LT-treated cells by a mechanism other than in-
activating the proteasome machinery.
Identified Compounds Inhibit Cdc25B In Vitro,
but Not in Toxin-Treated Macrophages
Because the identified compounds do not directly inhibit
anthrax LF enzymatic activity in vitro, this stronglyer Ltd All rights reserved
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compounds, NSC 95397 and NSC 135880, were previ-
ously reported by Lazo and coworkers [14] as Cdc25
dual-specificity phosphatase inhibitors. To determine if
the identified compounds inhibited Cdc25B activity, we
tested them in an in vitro phosphatase assay. The iden-
tified compounds exhibited a broad range of Cdc25B in-
hibition. Table 1 shows the chemical structures of the
five inhibitors, their percentage phosphatase inhibition at
concentrations of 10 mM, and their ED50 values (obtained
from the cell-based MTT assay).
Cdc25B is a dual-specific phosphatase that regulates
the entry of all eukaryotic cells into mitosis by activating
the cdc2/cyclin B mitotic kinase complex [15]. Although
activation of cdc2 during progression into mitosis is con-
trolled at several different steps, the critical regulatory
step is dephosphorylation of its Thr14 and Tyr15 residues
[16, 17]. To investigate if Cdc25B was a cellular target in-
volved in anthrax LT-induced cell death, we determined
the phosphorylation state of cdc2 and if G2/M arrest oc-
curred in J774A.1 macrophages following compound
treatment. Cell lysates from compound-treated macro-
phages did not show increased phosphorylation of cdc2
either by western blotting or after immunoprecipitation of
the cdc2/cyclin B complex. In addition, the macrophages
did not exhibit G2/M arrest following compound treat-
ment, although G2/M arrest could be achieved using
Table 1. Chemical Structures of Small-Molecule
Inhibitors with Percent Cdc25B Inhibition at
a Compound Concentration of 10 mM, and ED50
Values for Macrophage Protection
Structure
NSC
Number
% Inhibition
(Cdc25B)
ED50
(mM)
135880 99 25.0
95397 83 6–12
270012 72 6–12
148596 67 —
270011 25 6–12Chemistry & Biology 14, 24nocodozole (data not shown). Thus our data suggest
that Cdc25Bwas not involved in anthrax LT pathogenesis.
The Compounds Prevent Cleavage of MAPKK
andActivateDownstreamMAPK-SignalingMolecules
Anthrax LF, a Zn2+-dependent metalloprotease, cleaves
several isoforms of MAPKK (MEK), including MEK1,
MEK2, MEK3, MEK4, MEK6, and MEK7, but not MEK5
[3, 18, 19]. To determine the MEK cleavage pattern in
the macrophages, cell lysates prepared from J774A.1
cells pretreated with NSC 95397 or NSC 270012
(20 mM), in the presence or absence of anthrax LT, were
analyzed by western blotting using antibodies to the
MEK isoforms MEK1, MEK2, MKK3, and MKK4. As seen
in Figure 2A, the compounds partially to completely pro-
tected each of these four isoforms of MEK, which corre-
lates with the observed protection against cytotoxicity
after toxin and compound treatment (Figure 1).
Cleavage of the different isoforms of MEK by anthrax LT
disrupts downstream signaling to molecules including the
extracellular regulated kinases (ERK1 and ERK2, also
called p44/42), p38 kinase, and SAPK/JNK. Because we
observed partial to complete protection from enzymatic
cleavage of the different isoforms of MEK (Figure 2A),
we next examined the phosphorylation states of down-
stream MAPK-signaling molecules. We prepared cell ly-
sates from J774A.1 cells treated with or without toxin
and in medium containing DMSO (control), NSC 95397,
or NSC 270012 (20 mM). The lysates were analyzed by
western blotting using antibodies that recognize either the
phosphorylated or total levels of endogenous ERK1/2,
p38, and SAPK/JNK. Our results show that, compared
to control-treated J774A.1 cells, macrophages treated
with the compounds showed increased phosphorylation
of ERK1/2, p38, and SAPK/JNK, both in the absence
and presence of LT (Figure 2B). These results suggest
that, regardless of the toxin treatment, the compounds
were able to activate MAPK-signaling molecules. A time-
dependent study of the phosphorylation state of MAPK
revealed an increase in the phosphorylation states of
ERK1/2, p38, and SAPK/JNK within 60min in NSC 95397-
treated macrophages, compared to controls (Figure 2C).
Similar results were observed with NSC 270012 (data not
shown). Although control (medium containing DMSO) treat-
ment alone seemed to show high levels of phosphorylated
ERK1/2, densitometric scans from three independent ex-
periments showed a 1- to 3-fold fold increase in ERK1/2
phosphorylation in compound-treated macrophages (data
not shown). The observed increased phosphorylation
was more pronounced for ERK2 than ERK1.
MAPK Nuclear Translocation and Activation
of Transcription Factors
Once activated, MAPKs such as ERK1/2, p38, and SAPK/
JNK can either phosphorylate other kinases in the cyto-
plasm or they may translocate to the nucleus, where
they phosphorylate and activate nuclear proteins such
as transcription factors. To determine if activated p38
translocated to the nucleus following compound5–255, March 2007 ª2007 Elsevier Ltd All rights reserved 247
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Chemical Genetics to Understand Anthrax PathogenesisFigure 2. Partial to Complete Protection of MEK Cleavage and Activation of MAPK-Signaling Molecules by Bioactive Small
Molecules
J774A.1 cell lysates were treated with either medium containing DMSO (control) or anthrax toxin and in the presence or absence of compounds NSC
2700012 or NSC 95397 (20 mM). After 4 hr of incubation, cell lysates were prepared and analyzed bywestern blotting using antibodies to (A) MEK1NT,
MEK2 NT, MKK3, and MKK4 and (B) phospho- (P)-ERK1/2, P-p38, P-pSAPK/JNK, ERK1/2, p38, and transferrin receptor. (C) Macrophages were
treated with compound NSC95397 and at time points of 60, 120, and 240 min, and cell lysates were prepared and western blotted with antibodies
that recognize either the total p38 or phosphorylated ERK1/2, p38, SAPK/JNK. The control (‘‘C’’) lane is lysate prepared frommacrophages incubated
for 240 min in medium containing DMSO.treatment, we treated cells with medium containing
DMSO (control) or NSC 95397 (20 mM) for 4 hr. The cells
were then fixed, stained with p38 antibody, and visual-
ized by confocal microscopy (Figure 3A). Phosphorylated
p38 localized to the nucleus after compound treatment,
while nuclear staining of p38 was not observed in control
cells.
To determine if compound-activatedMAPKswere func-
tionally active and could phosphorylate specific transcrip-
tion factors, wemeasured kinase activity in protein lysates
from compound and/or toxin-treated cells using Elk-1,
ATF-2, and c-jun as substrates of the ERK1/2, p38, and
SAPK/JNK kinases, respectively. As shown in Figure 3B,
compound-activated MAPKs, in either the absence or
presence of the toxin, can phosphorylate their respective
substrates in vitro. Taken together, these studies suggest
that the compounds, through an unknown mechanism,
activated ERK1/2, p38, and SAPK/JNK MAPK-signaling
molecules, which then translocated to the nucleus and
phosphorylated transcription factors.
Induction of Proinflammatory Cytokines
Prior studies report that anthrax LT severely impairs the
ability of the macrophages to induce proinflammatory
cytokines [3, 21]. Because the compounds activated
MAPK signaling both in the absence and presence of
toxin, we next investigated if this induced production of
proinflammatory cytokines. We treated macrophages
with medium containing DMSO (control), NSC 95397, or
NSC 270012 for 4 hr in either the absence or presence
of toxin. Culture supernatants were analyzed for the248 Chemistry & Biology 14, 245–255, March 2007 ª2007 Elsevpresence of cytokines, including IL-12p70, MCP-1, TNF-a,
IL-10, and IL-6. The compounds, either in the absence
or presence of LT, induced high levels of TNF-a, while
LT alone impaired the ability of macrophages to secrete
TNF-a (Figure 4). There was no increase in secretion of
IL-12p70, IL-10, and IL-6 bymacrophages after compound
treatment (data not shown). The macrophages constitu-
tively produced high levels of MCP-1 (>5000 pg/ml), and
these levels were not altered after toxin and/or compound
treatment (data not shown). Our results suggest that
MAPK phosphorylation (Figure 3B) and the induction of
signals via TNF-a receptors most likely provide survival
signals to macrophages.
The Compounds Inhibit LT-Induced Apoptosis
in Macrophages
Anthrax LT induces apoptosis of susceptible [22] or acti-
vated macrophages [2]. To investigate if the compounds
inhibited LT-induced apoptosis, J774A1 macrophages
were incubated for 3 hr (Figure 5A, left panel) or 4 hr
(Figure 5A, right panel) with anthrax LT in the absence or
presence of different concentrations of NSC 95397 and
then stained with a mixture of YO-PRO-1, a green fluores-
cent dye that detects early apoptosis-specific changes in
membrane permeability, and PI, a late apoptosis/necro-
sis-specific red fluorescent dye. Hoechst dye (blue) was
used to stain the cell nuclei. Cells treated with the toxin
and compound showed a concentration-dependent inhi-
bition of apoptosis (Figure 5A, bottom panels) and in-
creased cell viability (Figure 5A, top panels) compared to
toxin control. Representative images of macrophagesier Ltd All rights reserved
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tom panel) show that fewer cells take up the apoptosis in-
dicator green fluorescent YO-PRO-1 dye (Figure 5B, left
panel) and the late apoptosis/necrosis red fluorescent PI
dye (Figure 5B, middle panel) compared to the toxin
control (Figure 5B, top panel).
DISCUSSION
To date, the cellular and molecular interactions between
B. anthracis virulence factors and host cells have been
poorly understood. Anthrax LT, a virulence factor pro-
duced by B. anthracis, turns off host immune responses
by disrupting MAPK-signaling pathways in immune cells
such as macrophages [1–4] and dendritic cells [5, 6].
This inhibits the clearance of the bacteria by phagocytosis
and ultimately results in massive bacteremia and toxemia.
Anthrax LT at high concentration causes cytolysis of sus-
ceptible J774A.1 macrophages. However, macrophages
from different inbred strains of mice vary in their sensitivity
to the lethal effects of anthrax LT [7, 23]. Furthermore,
macrophages resistant to LT-induced cell death still
exhibit MEK cleavage [7]. This indicates that there is no di-
rect relation between MEK cleavage and cell death, and
Figure 3. Activated p38 Is Translocated to the Nucleus and
Phosphorylates Transcription Factors In Vitro
(A) J774A.1 cells were treated with medium containing DMSO (control)
or NSC 95397 (20 mM) for 4 hr and then fixed, permeabilized, and
stained with p38 or phospho-p38 (P-p38) primary antibodies, which
were then detected using Alexa 568- or Alexa 488-conjugated second-
ary antibodies, respectively. The nucleus was stained with Hoechst
dye. Scale bar = 5 mm.
(B) The kinase activity of compound-activated ERK1/2, p38, and
SAPK/JNK signaling molecules was examined by in vitro kinase
assays using Elk-1, ATF-2, and c-jun as substrates respectively.Chemistry & Biology 14, 24hence additional cellular factors may play a role in LT-
induced cytotoxicity. A number of other cellular processes
or factors that have been reported to participate in anthrax
LT-induced cytotoxicity include proteasome activity [13],
intracellular calcium stores [24, 25], protein synthesis
[26], and reactive oxygen intermediates [27]. Recent stud-
ies by Wei et al. [28] show that low-density lipoprotein re-
ceptor-related protein 6 (LRP6), a cellular protein, is in-
volved in the internalization of the anthrax LT complex.
Intracellular signaling molecules like phosphatases have
also been implicated in anthrax LT-induced cytotoxicity
[20]. These studies suggest that anthrax LT modulates
a plethora of effects, and that the concerted action
of multiple cellular players is responsible for anthrax
pathogenesis.
Identifying critical pathways and host cell proteins that
play a key role in either the early stages of infection, or dur-
ing late stages when high levels of LT are produced, would
help researchers better understand the disease process
and help them develop novel therapeutic approaches. In
recent years, small organic molecules have been exten-
sively exploited as tools to perturb biological systems.
By activating or inactivating protein functions, compounds
identified in chemical genetic screens can help uncover
pathways and cellular targets involved in normal or dis-
ease processes [9, 29]. However, formidable problems
with using the chemical genetics approach include identi-
fying the cellular target proteins and possible indirect ef-
fects of the small molecules. Nonetheless, mechanistic
studies in combination with bioinformatics and biological
simulation models can provide clues to the compounds’
mechanisms of action, the interplay between different cel-
lular players, and the possible roles of associated targets
in pathogenesis.
Figure 4. Compounds Induce TNF-a Secretion
J774A.1 macrophages were untreated or treated with either LPS (100
ng/ml), medium containing DMSO, anthrax toxin (PA 80 ng/ml and LF
16 ng/ml), NSC 95397 (20 mM), NSC 270012 (20 mM), or a combination
of compound and toxin. After 4 hr, culture supernatants were
harvested and analyzed by cytometric bead array. The data represent
average ± SD macrophage responses from at least three individual
experiments.5–255, March 2007 ª2007 Elsevier Ltd All rights reserved 249
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Chemical Genetics to Understand Anthrax PathogenesisIn the present study, we used a chemical genetics
approach combined with a phenotypic screen to reveal
pathways and cellular targets that play a role in anthrax
LT-induced cell death. Small molecules from the NCI
Open Chemical Repository (>1000) were screened for
their ability to protect macrophages from the lethal action
of anthrax toxin. Subsequently, several compounds were
found to protect macrophages from LT-induced cyto-
toxicity, most likely by amechanism that activates MAPKs
and induces the proinflammatory cytokine TNF-a, both of
which may provide survival signals to macrophages. The
compounds show a concentration-dependent inhibition
of macrophage apoptosis, and their protective action is
not mediated by inhibition of LF, the proteosome, or the
Cdc25B phosphatase activity in anthrax LT-treated
macrophages.
One characteristic feature of the identified compounds
(NSC 95397, NSC 135880, NSC 270011, and NSC
270012; Table 1) is that they are all good electrophiles
and, thus, have the potential to modify amino and thiol
Figure 5. Compounds Inhibit Anthrax LT-Induced Apoptosis
(A) Representative data of J774A.1 macrophages incubated for 3 hr
(left panel) or 4 hr (right panel) with anthrax LT in the absence or pres-
ence of different concentrations of the compound NSC 95397. The
compound showed dose-dependent inhibition of LT-induced apopto-
sis (bottom panel) and increased cell viability (top panel).
(B) Representative images of macrophages treated with either anthrax
LT (top panels) or LT and NSC 95397 (25 mM; 4 hr incubation) (bottom
panels) and showing apoptosis as indicated by uptake of YO-PRO-1
green fluorescent dye (left panel) or late apoptosis/necrosis as indi-
cated by uptake of PI, a red fluorescent dye (middle panel). The right
panel shows green and red fluorescence merged with Hoechst stain-
ing of all nuclei (blue).250 Chemistry & Biology 14, 245–255, March 2007 ª2007 Elsgroups of the proteins indiscriminately. Despite these
seemingly ubiquitous structural motifs, studies by Lazo
et al. [14] have shown that compounds NSC 95397 and
NSC 135880 are potent and selective inhibitors of
Cdc25B compared with either the dual-specificity phos-
phatase VHR or the protein tyrosine phosphatase
PTP1B. One implication of these findings is the prospect
that specific modifications to the electrophilic phenan-
threne and naphthalene dione scaffolds of NSC 135880
and NSC 95397 (respectively) may generate greater spec-
ificity for their intended target. This is particularly interest-
ing given that these compounds demonstrated irrevers-
ible binding, thus signifying the likelihood of covalent
modification of Cdc25B.
Although Cdc25 dual-specificity phosphatases are im-
portant regulators of cell cycle control and mitogenic sig-
nal transduction, our cell cycle experiments showed that
Cdc25B was not the cellular target of the compounds in
macrophages. An interesting observation during the cell
cycle study was that cells arrested in the G2/M phase
using nocodozole were less susceptible to anthrax LT-
induced death compared to cells that were released
from G2/M arrest and then treated with LT (Figure S1).
The functional significance of this observation remains to
be determined.
In our study, the compounds NSC 95397 and NSC
270012 induced the phosphorylation of MAPK-signaling
molecules (ERK1/2, p38, and SAPK/JNK) in J774A.1mac-
rophages. Induced phosphorylation of ERK1/2 by NSC
95397 and its hydroxyl derivatives, aswell asCpd 5, a nap-
thoquinone derivative, and PM-20, a phenyl maleimide,
has recently been reported in Hep3B human hepatoma
cell line [30, 31]. A fluorinated derivative of Cpd5, also in-
duced the phosphorylation of ERK1/2, p38, and JNK1/2
signaling in Hep3B cells [32]. The induced phosphoryla-
tion of ERK1/2 in Hep3B cells is likely due to inhibition
of an (as yet) undefined ERK phosphatase(s) activity
but not of the dual-specificity ERK phosphatase
MKP-1 [30–32].
The exact mechanism of how the identified compounds
protect macrophages remains unclear. One possibility is
that the compounds may be preventing the entry of LF
into the cells. However, our in vitro ELISA studies (data
not shown) revealed that the LF can bind to (PA63)7 in
the presence of NSC 95397. Since this compound does
not interfere with the interaction of LF with (PA63)7, this
suggests that LF can enter the cells in the presence of
the compound. In a recent study, Kau et al. [20] hypothe-
sized that hyperphosphorylated MEK1 protein may not
be a suitable target for anthrax LT. However, we did not
observe hyperphosphorylation of MAPKK after treating
macrophages with our compounds (data not shown). In
addition we found that anthrax LF in vitro cleaved both
the phosphorylated and nonphosphorylated forms of
MEK (Figure S2). Thus the observed protection in our
cell-based assay was not due to the inability of LT to
cleave hyperphosphorylated MAPKK. To address the
question regarding why active LF cannot efficiently cleave
endogenous MAPKK, microarray and protein arrayevier Ltd All rights reserved
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pounds on the macrophages in presence of anthrax toxin.
An interesting observation in our study was the concen-
tration-dependent inhibition of LT-induced apoptosis by
the compounds. This effect could be mediated through
the activated MAPK-signaling pathway and, perhaps,
specifically by activated p38. Prior studies by Park et al.
[2] showed that survival of activated macrophages de-
pends upon the activity of p38 and NF-kB signaling mole-
cules. After macrophage activation, the p38-dependent,
antiapoptotic signal is relayed to the cAMP-responsive
transcription factor (CREB), which in turn synergizes with
NF-kB to induce the transcription of two antiapoptotic
genes, serpin plasminogen-activator inhibitor 2 (PAI-2)
and Bfl-1/A1 [33]. It has also been shown that in activated
human monocytes, phosphorylated p38 stabilizes TNF-a
and antiapoptotic Bcl2 mRNA transcripts [34] and
protects against TNF-a-mediated apoptosis [35].
Alternatively, crosstalk betweenTNF receptors,MAPKs,
and NF-kB may account for the compound-induced
protection against LT-mediated cytotoxicity. Ligation of
TNF-a to its receptors can induce phosphorylation of
p38, SAPK/JNK, and ERK signaling molecules [36–38].
Activated ERK phosphorylates TNF receptors in macro-
phages [39, 40], which protects these cells from apoptosis
in a silicosismodel [41].Moreover, TNF receptor-activated
NF-kB signals also protect cells from apoptosis by induc-
ing expression of TRAF1/2 and cIAP1/2 genes [42].
Based on the observations in this study and data from
the published literature (discussed above), we propose
a model for how the compounds may be protecting mac-
rophages from anthrax LT-induced cell death (Figure 6). In
particular it appears that the nature of the stimulus and the
triggered signaling pathways determine either apoptotic
or antiapoptotic responses (Figure 6A). For example, acti-
vation of Toll-like receptor 4 (TLR4) induces macrophage
apoptosis through signaling pathways that are not yet
well characterized [43]. On the other hand, TLR4 activation
can also initiate antiapoptotic responses through activa-
tion of p38 MAPK-signaling pathways. The pathogen
B. anthracis produces LF, a virulence factor that inhibits
MAPK activation. This contributes to the apoptosis of
activated macrophages [2]. In our study, the compound-
induced activation of MAPKs triggered an antiapoptotic
response (Figure 6B). This response may be mediated
via activation or inactivation of unidentified cellular fac-
tor(s) or inhibition of phosphatase(s) downstream of the
MAPKK-signaling molecules. Activated MAPKs may syn-
ergize with NF-kB to induce antiapoptotic gene expres-
sion resulting in survival of the LT-treated macrophages.
Alternatively, induced secretion of cytokines like TNF-a
by the compounds may be responsible for activating
MAPK-signaling molecules. Our data did not distinguish
whether the compounds or the induced TNF-a that acti-
vated the MAPK-signaling molecules. The contribution
of activated SAPK/JNK signaling molecules in com-
pound-induced cell survival still remains to be determined.
Although our study did not identify the direct target(s) of
our protective compounds in macrophages, we did ruleChemistry & Biology 14, 2out several leading hypotheses and highlighted the impor-
tance of activated p38 and ERK1/2 to macrophage sur-
vival. This demonstrates the power of applying a chemical
genetic approach to the study of host-pathogen inter-
actions for identifying the host proteins and pathways
involved in infection and disease progression. This
approach can be exploited to identify the key host players
in other pathogenic systems, both to better understand
the disease process and to identify host-based therapeu-
tic targets, which may be more effective against resistant
bacterial strains or engineered biothreat organisms.
SIGNIFICANCE
Chemical genetics involves the use of small molecules
as probes to perturb dynamic cellular processes,
thereby helping define critical pathways and factors
involved in health and disease. In this study, we
employed molecular scaffolds with pharmacophoric
diversity to identify compounds that protectedmacro-
phages from the lethal action of the anthrax toxin.
Next, we selected the subset of active compounds
that lacked direct inhibitory activity on LF or the cellu-
lar proteasome in order to explore downstream tar-
gets related to the anthrax toxin mechanism of action.
Interestingly, compounds fulfilling these criteria were
previously identified as inhibitors of a downstream tar-
get to Cdc25 dual-specificity phosphatases, thus ex-
posing a common link between targets of interest for
cancer and bioterror therapeutics. Subsequent inves-
tigations demonstrated that these compounds induce
the phosphorylation of MAPK-signaling molecules
and the production of the proinflammatory cytokines
such as TNF-a. We propose that induction of anti-
apoptotic responses via MAPK-dependent or -inde-
pendent pathways and the activation of host innate
responses may protect macrophages from anthrax
LT-induced cell death. More importantly, this type of
chemical genetic approach can provide new insights
into the function of several signaling pathways during
the pathogenesis of multiple diseases that share com-
mon downstream pathways.
EXPERIMENTAL PROCEDURES
The Compounds
Small molecules examined in this study were obtained from the NCI
Open Chemical Repository. The chosen compounds comprise a range
of molecular scaffolds covering a diversity of pharmacophoric space.
Based on the structure of NSC 95397, related napthoquinone- and
dione-containing derivatives were subsequently examined.
Cell-Based Cytotoxicity Assay
J774A.1 macrophages were preincubated with medium containing
2% DMSO (control) or different concentrations of the NCI compounds
ranging from 0 to 25 mM. After 30min, cells were treatedwith PA (80 ng/
ml) and LF (16 ng/ml). After a 4 hr incubationwith the toxin, 25 ml of MTT
(1 mg/ml) dye was added and the cells were further incubated for 2 hr.
The reaction was stopped by adding an equal volume of lysis buffer
(50% DMF and 20% SDS [pH 4.7]). Plates were incubated overnight
at 37C and absorbance read at 570 nm in a multiwell plate reader.45–255, March 2007 ª2007 Elsevier Ltd All rights reserved 251
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Chemical Genetics to Understand Anthrax PathogenesisFigure 6. Proposed Model of LT-Treated Macrophage Survival Based on our Mechanistic Studies and Published Literature
(A) Different stimuli can trigger apoptotic and antiapoptotic pathways [2, 33, 35–40, 42]. TLR4 activation can induce either an apoptotic response or,
via MAPK activation, can trigger antiapoptotic response. Anthrax LF cleaves MAPKK and disrupts downstream signaling events, thereby inducing
apoptosis of susceptible macrophages.
(B) Compounds, via inhibition of protein phosphatases (PP) or activation/inactivation of unknown cellular factor(s), activateMAPK-signalingmolecules
and thereby trigger antiapoptotic response. Alternatively, induction of proinflammatory cytokines like TNF-a by the compound may activate MAPK-
signaling molecules.In Vitro Cdc25b Phosphatase Assay
The in vitro activity of the Cdc25B phosphatase was measured as de-
scribed previously [14, 44]. Briefly, reaction mix (25 ml) containing as-
say buffer (30 mM Tris [pH 8.0], 75 mM NaCl, 1 mM EDTA, 0.033%
BSA, and 1 mM DTT), 40 mM of 3-O-methyl fluorescein phosphate
(OMFP) substrate, 0.7 mg/ml of His-Cdc25B catalytic domain, and
compound or DMSO (control) was incubated for 1 hr at room temper-
ature. Removal of the phosphate group from the substrate by Cdc25B
caused an increase in fluorescence that wasmeasured at an excitation
wavelength of 485 nm and emission wavelength of 530 nm.
HPLC-Based LF Assay
The HPLC-based LF assay was carried out as described previously
[11]. Briefly, the reaction was set up in a 30 ml volume. Master mix con-252 Chemistry & Biology 14, 245–255, March 2007 ª2007 Elsetaining 40mMHEPES buffer (pH 7.2), 0.05% Tween 20, 100 mMCaCl2,
and 1 mg/ml of LF was added to each tube containing 20 mM peptide
and 10 mM of select compounds. The reaction mixture was incubated
for 30 min at 30C and then stopped by adding solution containing 8 M
guanidine hydrochloride and 0.3% TFA. The cleaved products were
separated on a Hi-Pore C18 column (Bio-rad laboratories, Richmond,
CA) using 0.1% TFA (solvent A) and 0.1% TFA/70% acetonitrile
(solvent B). The column effluent was monitored at 365 nm, where
the substrate and C-terminal cleavage products showed stronger
absorbance.
Measurement of Proteasome Activity
J774A.1macrophages were lysed by sonication (33 5 s pulses) in pro-
teasome buffer (50mMTris [pH 7.5], 140mMNaCl, 5mMMgCl2, 1mMvier Ltd All rights reserved
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cocktail). After centrifugation, cell extracts containing 40 mg of total
proteinwere incubatedwith 100 mMof the different fluorogenic peptide
substrates (SLLVY-AMC, Z-LLE-AMC, and Z-VKM-AMC) and in the
presence of the compounds NSC 270012 or NSC 95397 (20 mM), or
proteasome inhibitor MG132 (10 mM). Kinetic measurements were
made every minute for 30 min at an excitation and emission maxima
of 380 and 460 nm, respectively, using a fluorescence plate reader
(Tecan, Safire).
Immunoblot Analysis
J774A.1 macrophages (13 106) seeded in a six-well plate were pre-
incubated for 30 min at 37C with either medium containing DMSO
(control) or with 20 mM of the compounds NSC 95397 or NSC
270012. Anthrax LT (80 ng/ml PA and 16 ng/ml LF) was added to the
appropriate wells and further incubated for various time points as indi-
cated in the figure legends. Macrophages were harvested and lysed in
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mMNaCl, 2 mM EDTA,
25 mM b-glycerophosphate, 1% Triton X-100, 10 mM NaF, 1 mM
sodium orthovanadate, protease inhibitor cocktail (Sigma), and phos-
phatase inhibitor cocktail I and II (Sigma). The cell lysates were incu-
bated for 30 min on ice, and insoluble material was removed by centri-
fugation. Cell extracts (30 mg) were electrophoresed on SDS-PAGE
and then subjected to western blotting. Immunoreactive proteins
were visualized by enhanced chemiluminescence (ECL).
Antibodies
Antibodies used in this study included antibodies that recognize p38
and phospho-p38MAP kinase, ERK1/2 and phospho-ERK1/2 MAP ki-
nase, and phospho-SAPK/JNK and pan-SAPK/JNK. These were all
purchased from Cell Signaling Technology, Beverly, MA. Anti-MEK1
NT was from Upstate Biotechnology, while antibodies to MKK2 NT,
MKK3 C-19, and MKK4 C-20 were from Santa Cruz Biotechnology.
Live Imaging and Confocal Microscopy
For live imaging studies, J774A.1 macrophages were treated either
with toxin (80 ng/ml PA and 16 ng/ml LF) diluted in medium containing
DMSO (2%) or with toxin and NSC 95397 (20 mM). Live imaging of the
cells was carried out in the presence of the membrane-impermeable
nucleic acid dye SYTOX green (Molecular Probes, Eugene OR) over
a period of 4 hr using aNikon TE300 invertedmicroscopewith a heated
enclosure to maintain the cells at 37C. Bright-field and fluorescence
image pairs were collected at 10 min intervals with a SPOT RT CCD
camera (Diagnostic Instruments, Sterling Heights, MI) and two Uniblitz
shutters (Vincent Associates, Rochester, NY) controlled byMetaMorph
imaging software (Molecular Devices Corporation, Downingtown, PA).
To determine the subcellular localization of activated p38, J774A.1
grown on chambered coverslips were incubatedwithmedium contain-
ing DMSO (control) or NSC 95397 (20 mM) for 4 hr and then fixed with
3.7% formaldehyde and permeabilized in 0.2% Triton X-100 for 15min
at room temperature. The cells were blocked overnight at 4C in buffer
consisting of 3% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS), incubated with primary antibody overnight at 4C,
washed three times with PBS, and then treated with the appropriate
Alexa 488- or Alexa 568-conjugated secondary antibodies for 1 hr at
37C. The cells were washed three times with PBS and then treated
with Hoechst dye to stain the cell nuclei. Fluorescence was visualized
using a Bio-Rad 2000MP confocal/multiphoton system attached to
a Nikon TE300 inverted microscope. Images of cells with and without
compound were collected using identical settings, and any subse-
quent contrast enhancement was likewise performed identically.
Kinase Assays
J774A.1macrophageswere preincubated with eithermedium contain-
ing DMSO (control) or NSC 95397 alone for 30 min and then further
incubated in the absence or presence of anthrax LT (80 ng/ml PA
and 16 ng/ml LF). After 4 hr incubation, cell lysates were prepared in
lysis buffer (detailed in western blot analysis) containing 1% TritonChemistry & Biology 14, 2X-100 and protease and phosphatase inhibitor cocktails. The insoluble
cellular debris was removed by centrifugation. The protein concentra-
tion of the resulting supernatant was determined. To measure MAPK
activity in the lysates, a nonradioactive kinase assay kit was used as
per manufacturer’s instructions (Cell Signaling Technologies). Briefly,
phosphorylated ERK1/2, p38, or SAPK/JNK proteins were immuno-
precipitated from 200 mg of cell lysate with appropriate antibodies,
and an in vitro kinase assay was performed using Elk-1, ATF-2, and
c-jun proteins as substrates, respectively. The phosphorylated
substrates were detected by immunoblotting with phospho-
substrate-specific antibodies.
Cytokine Measurement
Culture supernatants collected from J774A.1 macrophages treated
with either LPS (100 ng/ml), medium containing DMSO, anthrax LT
(80 ng/ml PA and 16 ng/ml LF), NSC 95397 (20 mM), NSC 270012
(20 mM), or a combination of compound and toxin were analyzed for
secreted proteins using themouse inflammation cytometric bead array
kit (BD Biosciences, San Jose, CA) according to the manufacturer’s
directions. All analyses were performed on a FACSCalibur (BD Bio-
sciences).
Apoptosis/Necrosis Assay
J774A.1 macrophages (1 3 104 cells/well) were seeded in a 96-well
plate. The next day, cells were treated with either medium containing
DMSO (control) or with anthrax lethal toxin (80 ng/ml PA and
16 ng/ml LF) in the absence or presence of different concentrations
of the compound NSC 95397. After incubation for 3 or 4 hr, medium
was removed and cells were incubated for 20 min with a mix of
YO-PRO-1 (0.5 mM) and propidium iodide (PI; 10 mg/ml) indicator
dyes diluted in PBS. Cells were washed and fixed in 1.8% paraformal-
dehyde. Cells were then stained with Hoechst dye, and images from
nine sites per well collected and analyzed using the Discovery-1
high-content screening system (Molecular Devices, Downingtown,
PA). Images were analyzed with the Cell Health module of MetaXpress
imaging analysis software. Total cell counts were based on number of
Hoechst-stained cell nuclei, while colocalization with YO-PRO-1 stain-
ing was scored as early apoptotic, colocalization with PI staining was
scored as necrotic, and colocalization with both YO-PRO-1 and PI
together was scored as late apoptotic.
Supplemental Data
Supplemental Data include two figures and two movies and can
be found at http://www.chembiol.com/cgi/content/full/14/3/245/
DC1/.
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